7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A deep dive into how East Asian pharmacogenomics, NNMT activity, CYP2C19/CYP2D6 variants, and lower BMI thresholds, shape NMN and NR efficacy, with ethnicity-stratified trial data and dosing guidance.
Hispanic and Latino patients face unique pharmacogenomic and metabolic factors that may alter NMN and NR efficacy. This evidence-based review covers trial data, enzyme variants, dosing considerations, and what clinicians need to know.
A clinically detailed guide to NMN and NR dosing considerations for patients of Black and African ancestry, covering pharmacogenomics, NAD+ biology, relevant comorbidity patterns, and practical prescribing guidance.
Evidence-based guide to NMN and NR dose adjustments for East Asian patients, covering pharmacogenomic variants, BMI thresholds, NAD+ metabolism differences, and practical clinical recommendations.
Evidence-based review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety profiles in East Asian populations, including pharmacogenomic variants, dosing considerations, and monitoring recommendations.
A clinical review of NMN and NR safety, pharmacogenomics, and dosing considerations specific to Black and African ancestry patients, including G6PD prevalence, NAD+ metabolism, and hypertension interactions.
A guide to NMN and NR pharmacogenomics, dosing considerations, and safety differences relevant to Hispanic and Latino patients, including CYP2E1 variants, diabetes prevalence, and ethnicity-stratified trial data.